argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus Transcript
Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. (Operator Instructions)
I would now like to turn the conference over to Beth DelGiacco, Vice President of Corporate Communications and Investor Relations. Please go ahead.
&
Thank you and to everyone for joining us today. A press release was issued this morning with the top line results from the address study of Efgartigimod SC in Pemphigus. We have a short slide deck to accompany our remarks this morning, which is also available on the Investors section of our website for your reference.
Before we begin, I would like to remind you on slide 2 that forward-looking statements may be presented during this call is may include statements about our future
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |